YOUNT, INC.
BROOMFIELD, CO
10/8/2014
Matthew Henderson
Yount, Inc.
Broomfield, CO
Mr. Angel
Dear Mr. Angel
We are excited to announce the extension of Yount, Inc. to an international stage! As you may be aware, Yount, Inc. is well known in the U.S. medical industry as the leader in medical technology. Yount, Inc. is most widely recognized for its landmark Na-No-CancerTM nano-robot which delivers a molecular payload to cancer cells, programming them to self-destruct. With the help of your contribution, we are proud and excited to share our revolutionary medical technology vision with the rest of the world. Our initial goal is to introduce our technology with the medical markets of Canada and Italy, and to establish a manufacturing plant in Brazil.
Yount, Inc. has determined that the Na-No-CancerTM nanobot does not violate either the Export Administration Act of 1985 or the Arms Export Control Act. Furthermore, Yount, Inc. has already acquired an approval from the U.S. Food and Drug Administration (FDA) and has an export certificate from them. This means that Yount, Inc. is in compliance with the Federal Food, Drug and Cosmetics (FD&C) Act. We are confident that we have met all of our legal obligations in this venture.
Yount has identified two companies with whom it is negotiating contracts: MedItalia in Italy and MedCanada in Canada. We have chosen these two companies based on their exemplary reputation and their relationships with their respective governments. We have built a strong relationship with these two companies and are in the process of negotiating contracts.
In both cases we have all agreed that the Contracts for the International Sale of Goods (CISG) is the most agreeable choice of law. This will prevent any bias and/or prejudice on behalf of any one government or company. This will also ensure that any changes in contract will affect all parties involved.
Yount, Inc. has firmly held that any resolutions should made in Colorado courts. This will enable Yount to modify or adapt in a timely manner.
Because of the revolutionary nature of our product, we are determined to use English as the language of our contract. MedCanada has agreed to these terms, however; MedItalia is still considering these terms. We have already encountered translation hardships attempting to explain our devices and procedures in Italian. We believe MedItalia will see these complications and agree to our English terms.
All of the involved countries have strong economies, however; we believe that, despite our current recession, the United States economy is the most reliable. MedCanada has agreed to a contract using US Dollars. We are in negotiation with MedItalia regarding the US Dollar or the Italian Euro. We believe that it is in our best interest to rely on the US Dollar, however; we are willing to be flexible in negotiations of currency with MedItalia.
In both cases, Yount will require a letter of credit from MedCanada and MedItalia. We believe this will keep all parties financially responsible, protected and accountable. This will also keep Yount accountable for accuracy in shipping.
The nature of medical practices in Canada and Italy are very well understood by MedCanada and MedItalia, respectively. Yount, Inc. has made a name for itself on a worldwide stage with its Na-No-CancerTM nanobot. Our research shows that there is high demand for our product in Canada and Italy. Because of the socialized nature of medicine, we believe that national negotiations are best left to MedItalia and MedCanada. We have all agreed to a licensing agreement which will give all parties the flexibility and accountability to effectively accomplish our goals.
The North American Free Trade Agreement (NAFTA) enables Yount, Inc. and MedCanada to trade freely. As a member of the European Union (EU), Italy is bound by EU treaties and laws. This makes trade with MedItalia slightly more challenging. We at Yount, Inc. are ready to meet this challenge.
Finally, Yount, Inc. is opening a manufacturing plant in Brazil. We have located some land near the city of São Luis in the State of Maranhão where we would like to begin development of our plant.
Yount, Inc. is aware of the ethical implications regarding this venture and we want to ensure our investors and other stakeholders that we are approaching this move with a utilitarian philosophy. We hope to bring the most good for the greatest number of people. That includes our stakeholders, investors, and the good people of Brazil and São Luis. It is our hope to bring economic stimulation to the region with new jobs and fair pay. We are also taking environmental precautions to reduce our waste and leave little impact on the Brazilian eco-system. We are aware of the Foreign Corrupt Practices Act (FCPA) and we can assure you that Yount, Inc. is directly involved in every aspect of this venture and we’ve placed Yount employed ethics officers along the way to ensure that we maintain the standards which make Yount, Inc. so reliable.
Your contribution is greatly appreciated.
To Your Heath,
Matthew Henderson
Account Executive
Yount, Inc.
BROOMFIELD, CO
10/8/2014
Matthew Henderson
Yount, Inc.
Broomfield, CO
Mr. Angel
Dear Mr. Angel
We are excited to announce the extension of Yount, Inc. to an international stage! As you may be aware, Yount, Inc. is well known in the U.S. medical industry as the leader in medical technology. Yount, Inc. is most widely recognized for its landmark Na-No-CancerTM nano-robot which delivers a molecular payload to cancer cells, programming them to self-destruct. With the help of your contribution, we are proud and excited to share our revolutionary medical technology vision with the rest of the world. Our initial goal is to introduce our technology with the medical markets of Canada and Italy, and to establish a manufacturing plant in Brazil.
Yount, Inc. has determined that the Na-No-CancerTM nanobot does not violate either the Export Administration Act of 1985 or the Arms Export Control Act. Furthermore, Yount, Inc. has already acquired an approval from the U.S. Food and Drug Administration (FDA) and has an export certificate from them. This means that Yount, Inc. is in compliance with the Federal Food, Drug and Cosmetics (FD&C) Act. We are confident that we have met all of our legal obligations in this venture.
Yount has identified two companies with whom it is negotiating contracts: MedItalia in Italy and MedCanada in Canada. We have chosen these two companies based on their exemplary reputation and their relationships with their respective governments. We have built a strong relationship with these two companies and are in the process of negotiating contracts.
In both cases we have all agreed that the Contracts for the International Sale of Goods (CISG) is the most agreeable choice of law. This will prevent any bias and/or prejudice on behalf of any one government or company. This will also ensure that any changes in contract will affect all parties involved.
Yount, Inc. has firmly held that any resolutions should made in Colorado courts. This will enable Yount to modify or adapt in a timely manner.
Because of the revolutionary nature of our product, we are determined to use English as the language of our contract. MedCanada has agreed to these terms, however; MedItalia is still considering these terms. We have already encountered translation hardships attempting to explain our devices and procedures in Italian. We believe MedItalia will see these complications and agree to our English terms.
All of the involved countries have strong economies, however; we believe that, despite our current recession, the United States economy is the most reliable. MedCanada has agreed to a contract using US Dollars. We are in negotiation with MedItalia regarding the US Dollar or the Italian Euro. We believe that it is in our best interest to rely on the US Dollar, however; we are willing to be flexible in negotiations of currency with MedItalia.
In both cases, Yount will require a letter of credit from MedCanada and MedItalia. We believe this will keep all parties financially responsible, protected and accountable. This will also keep Yount accountable for accuracy in shipping.
The nature of medical practices in Canada and Italy are very well understood by MedCanada and MedItalia, respectively. Yount, Inc. has made a name for itself on a worldwide stage with its Na-No-CancerTM nanobot. Our research shows that there is high demand for our product in Canada and Italy. Because of the socialized nature of medicine, we believe that national negotiations are best left to MedItalia and MedCanada. We have all agreed to a licensing agreement which will give all parties the flexibility and accountability to effectively accomplish our goals.
The North American Free Trade Agreement (NAFTA) enables Yount, Inc. and MedCanada to trade freely. As a member of the European Union (EU), Italy is bound by EU treaties and laws. This makes trade with MedItalia slightly more challenging. We at Yount, Inc. are ready to meet this challenge.
Finally, Yount, Inc. is opening a manufacturing plant in Brazil. We have located some land near the city of São Luis in the State of Maranhão where we would like to begin development of our plant.
Yount, Inc. is aware of the ethical implications regarding this venture and we want to ensure our investors and other stakeholders that we are approaching this move with a utilitarian philosophy. We hope to bring the most good for the greatest number of people. That includes our stakeholders, investors, and the good people of Brazil and São Luis. It is our hope to bring economic stimulation to the region with new jobs and fair pay. We are also taking environmental precautions to reduce our waste and leave little impact on the Brazilian eco-system. We are aware of the Foreign Corrupt Practices Act (FCPA) and we can assure you that Yount, Inc. is directly involved in every aspect of this venture and we’ve placed Yount employed ethics officers along the way to ensure that we maintain the standards which make Yount, Inc. so reliable.
Your contribution is greatly appreciated.
To Your Heath,
Matthew Henderson
Account Executive
Yount, Inc.
No comments:
Post a Comment